Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: The Louis F. Bishop lecture

Journal of the American College of Cardiology

Volumn 46, Issue 7, 2005, Pages 1219-1224

  Gotto Jr , Antonio M ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; ETC 216; PRAVASTATIN; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY RISK; DISEASE CLASSIFICATION; DYSLIPIDEMIA; HEALTH CARE POLICY; HORMONE SUBSTITUTION; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; RISK FACTORS;

EID: 27744577837     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.059     Document Type: Review

References (48)

1. D. Steinberg An interpretive history of the cholesterol controversy part 1 J Lipid Res 45 2004 1583 1593
2. D. Steinberg An interpretive history of the cholesterol controversy: part 2: the early evidence linking hypercholesterolemia to coronary disease in humans J Lipid Res 46 2005 179 190
3. N.J. Mehta, I.A. Khan Cardiology's 10 greatest discoveries of the 20th century Tex Heart Inst J 29 2002 164 171
4. A. Gotto, H. Pownall Manual of Lipid Disorders Reducing the Risk for Coronary Heart Disease 3rd edition 2003 Lippincott, Williams, and Wilkins New York, NY 70
5. R.E. Olson Discovery of the lipoproteins, their role in fat transport and their significance as risk factors J Nutr 128 1998 439S 443S
6. E.J. Cohn, L.E. Strong, W.L. Hughes Jr. Preparation and properties of serum and plasma lipoproteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids J Am Chem Soc 68 1946 459 475
7. J.L. Oncley, G. Scatchard, H.V. Brown Physical-chemical characteristics of certain of the proteins of normal human plasma J Phys Colloid Chem 51 1947 184 198
8. E.M. Russ, H.A. Eder, D.P. Barr Protein-lipid relationships in human plasma I. In normal individuals Am J Med 11 1951 468 479
9. D.P. Barr, E.M. Russ, H.A. Eder Protein-lipid relationships II. In human plasma in atherosclerosis and related conditions Am J Med 11 1951 480 493
10. J.W. Gofman, F.T. Lindgren, H. Elliott Ultracentrifugal studies of lipoproteins of human serum J Biol Chem 179 1949 973 979
11. D.S. Fredrickson, R.I. Levy, R.S. Lees Fat transport in lipoproteins - an integrated approach to mechanisms and disorders N Engl J Med 276 1967 34 44 94-103, 148-56, 215-25, 273-81, 321-7
12. A. Keys Coronary heart disease in seven countries. American Heart Association Monograph 29 Circulation 41 1970 1 211
13. W.B. Kannel, T.R. Dawber, A. Kagan, N. Revotskie, J. Stokes III Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study Ann Intern Med 55 1961 33 50
14. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
15. D.S. Steinberg, S. Blumenthal, B.A. Carleton NIH Consensus Development Conference on Lowering Blood Cholesterol to Prevent Heart Disease. Lowering blood cholesterol to prevent heart disease: NIH consensus development conference statement Arteriosclerosis 12 1985 404 412
16. M.H. Frick, O. Elo, K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
17. T.J. Moore The cholesterol myth Atlantic Monthly 264 1989 37
18. M.L. Dansinger, J.A. Gleason, J.L. Griffith, H.P. Selker, E.J. Schaefer Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction a randomized trial JAMA 293 2005 43 53
19. D.J. Graham, J.A. Staffa, D. Shatin Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
20. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
21. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
22. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
23. R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, E.S. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
24. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
25. V. Manninen, L. Tenkanen, P. Koskinen Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment Circulation 85 1992 37 45
26. H.B. Rubins, S.J. Robins, D. Collins Diabetes, plasma insulin, and cardiovascular disease subgroup analysis from the Department of Veterans Affairs High-density lipoprotein Intervention Trial (VA-HIT) Arch Intern Med 162 2002 2597 2604
27. J.R. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
28. A.M. Gotto Jr., E. Whitney, E.A. Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484
29. H.B. Brewer Jr High-density lipoproteins a new potential therapeutic target for the prevention of cardiovascular disease Arterioscler Thromb Vasc Biol 24 2004 387 391
30. S.E. Nissen, T. Tsunoda, E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes a randomized controlled trial JAMA 290 2003 2292 2300
31. J.P. Segrest, R.L. Jackson, J.D. Morrisett, A.M. Gotto Jr A molecular theory of lipid-protein interactions in the plasma lipoproteins FEBS Lett 38 1974 247 253
32. R.W. Clark, T.A. Sutfin, R.B. Ruggeri Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 2004 490 497
33. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
34. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
35. J.C. LaRosa, S.M. Grundy, D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
36. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
37. L. Smeeth, S.L. Thomas, A.J. Hall, R. Hubbard, P. Farrington, P. Vallance Risk of myocardial infarction and stroke after acute infection or vaccination N Engl J Med 351 2004 2611 2618
38. J.T. Grayston Antibiotic treatment of atherosclerotic cardiovascular disease Circulation 107 2003 1228 1230
39. C.P. Cannon, E. Braunwald, C.H. McCabe Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome N Engl J Med 352 2005 1646 1654
40. E.J. Topol Arthritis medicines and cardiovascular events - "house of coxibs." JAMA 293 2005 366 368
41. P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe, M. Egger Risk of cardiovascular events and rofecoxib cumulative meta-analysis Lancet 364 2004 2021 2029
42. P.M. Ridker, N. Rifai, M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
43. P.M. Ridker, C.P. Cannon, D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
44. P.M. Ridker, D.A. Morrow, L.M. Rose, N. Rifai, C.P. Cannon, E. Braunwald Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol 45 2005 1644 1648
45. O. Stuve, S. Youssef, L. Steinman, S.S. Zamvil Statins as potential therapeutic agents in neuroinflammatory disorders Curr Opin Neurol 16 2003 393 401
46. T. Vollmer, L. Key, V. Durkalski Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
47. D.W. McCarey, I.B. McInnes, R. Madhok Trial of Atorvastatin in Rheumatoid Arthritis (TARA) double-blind, randomised placebo-controlled trial Lancet 363 2004 2015 2021
48. J.N. Poynter, S.B. Gruber, P.D.R. Higgins Statins and the risk of colorectal cancer N Engl J Med 353 2005 2184 2192